ElsevierDrugInformation
Nirsevimab Injection
Learn more about Elsevier’s Drug Patient Education today! Empower and engage your patients to use medication safely.
NIRSEVIMAB (nir sev i mab) reduces the risk of infections caused by respiratory syncytial virus (RSV). It does not treat RSV. It is still possible to get RSV after receiving this medication, but the symptoms may be less severe or not last as long. It works by helping your immune system slow or stop the spread of the virus in the body. It is a monoclonal antibody.
This medication is injected into a muscle. It is given by your care team in a hospital or clinic setting.
Talk to your care team about the use of this medication in children. While it may be given to children as young as newborns for selected conditions, precautions do apply.
Side effects that you should report to your care team as soon as possible:
Side effects that usually do not require medical attention (report these to your care team if they continue or are bothersome):
This medication is given in a hospital or clinic. It will not be stored at home.
They need to know if you have any of these conditions:
Interactions have not been studied.
This does not apply. This medication is not for regular use.
Visit your care team for regular checks on your health.
Cookies are used by this site. To decline or learn more, visit our cookie notice.
Copyright © 2024 Elsevier, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies.